Skip to main content
COAG logo

COAG · Hemab Therapeutics Holdings, Inc. · Executive Compensation

Track COAG — free
$38.71 -0.45 (-1.14%) Play latest call Q3 2026 earnings call transcript
Market Cap
$1.83B
Shares
46.73M
Volume · Nov 19 43.99K Avg daily vol (3M) 496.12K

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

No Compensation Data

No Summary Compensation Table has been imported from this company's proxy statements yet.

Executive changes

Person Change Filed
Keli Walbert Appointed 2026-09-24
Laura Tadvalkar, Ph.D.
“Dr. Tadvalkar’s resignation from the Board was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.”
Resigned 2026-05-11

Leadership

Key facts CIK 2114044 CUSIP 423494103 13F (30d) 89 filings 88 filers Visit website Investor relations